Abstract
The family of 5 muscarinic acetylcholine receptors belongs to the superfamily of G protein coupled neurotransmitter receptors that serve in part as regulators of synaptic function. Muscarinic receptors are anatomically positioned in cortical and subcortical areas and modulate dopaminergic and glutamatergic neurotransmission thought to be dysfunctional in schizophrenia. Neurochemical studies have shown that dopamine and muscarinic receptors reciprocally modulate one another. For example, the muscarinic agonist xanomeline increases extracellular levels of dopamine and Fos expression in cortical areas greater than subcortical areas, similar to effects of atypical antipsychotics. In electrophysiological studies, xanomeline with acute and chronic administration decreased firing of the mesocorticolimbic dopamine A10 tract, but not the motoric dopamine A9 tract. Behavioral investigations have shown that muscarinic agonists, like dopamine antagonists, inhibit conditioned-avoidance responding and dopamine-agonist-induced behaviors including hyperactivity, climbing behavior and disruption of prepulse inhibition, models for positive symptoms of schizophrenia. Transgenic knockout mice lacking M4 receptors are hyperactive and hyper-responsive to dopamine D1 agonists, suggesting a dynamic balance between the dopamine and M4 receptors. Muscarinic agonists had activity in animal models of negative symptoms, cognitive dysfunction and affective disorders, symptoms that are prominent in schizophrenic patients. Consistent with effects in animal models, preliminary clinical investigation indicates that muscarinic agonists like xanomeline may be effective in the pharmacotherapy of schiz ophrenia. Thus, we hypothesize that a combined M1 agonist to promote cognition and a M4 agonist for antipsychotic-like effects would treat the symptom domains of schizophrenia without parasympathomimetic side effects.
Keywords: muscarinic receptors, schizophrenia, psychosis, xanomeline, dopamine, acetylcholine, muscarinic agonists, alzheimers disease
Current Drug Targets - CNS & Neurological Disorders
Title: Muscarinic Receptors as a Target for Drugs Treating Schizophrenia
Volume: 1 Issue: 2
Author(s): Frank P. Bymaster, Christian Felder, Saeed Ahmed and David McKinzie
Affiliation:
Keywords: muscarinic receptors, schizophrenia, psychosis, xanomeline, dopamine, acetylcholine, muscarinic agonists, alzheimers disease
Abstract: The family of 5 muscarinic acetylcholine receptors belongs to the superfamily of G protein coupled neurotransmitter receptors that serve in part as regulators of synaptic function. Muscarinic receptors are anatomically positioned in cortical and subcortical areas and modulate dopaminergic and glutamatergic neurotransmission thought to be dysfunctional in schizophrenia. Neurochemical studies have shown that dopamine and muscarinic receptors reciprocally modulate one another. For example, the muscarinic agonist xanomeline increases extracellular levels of dopamine and Fos expression in cortical areas greater than subcortical areas, similar to effects of atypical antipsychotics. In electrophysiological studies, xanomeline with acute and chronic administration decreased firing of the mesocorticolimbic dopamine A10 tract, but not the motoric dopamine A9 tract. Behavioral investigations have shown that muscarinic agonists, like dopamine antagonists, inhibit conditioned-avoidance responding and dopamine-agonist-induced behaviors including hyperactivity, climbing behavior and disruption of prepulse inhibition, models for positive symptoms of schizophrenia. Transgenic knockout mice lacking M4 receptors are hyperactive and hyper-responsive to dopamine D1 agonists, suggesting a dynamic balance between the dopamine and M4 receptors. Muscarinic agonists had activity in animal models of negative symptoms, cognitive dysfunction and affective disorders, symptoms that are prominent in schizophrenic patients. Consistent with effects in animal models, preliminary clinical investigation indicates that muscarinic agonists like xanomeline may be effective in the pharmacotherapy of schiz ophrenia. Thus, we hypothesize that a combined M1 agonist to promote cognition and a M4 agonist for antipsychotic-like effects would treat the symptom domains of schizophrenia without parasympathomimetic side effects.
Export Options
About this article
Cite this article as:
Bymaster P. Frank, Felder Christian, Ahmed Saeed and McKinzie David, Muscarinic Receptors as a Target for Drugs Treating Schizophrenia, Current Drug Targets - CNS & Neurological Disorders 2002; 1 (2) . https://dx.doi.org/10.2174/1568007024606249
DOI https://dx.doi.org/10.2174/1568007024606249 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
The Biochemical and Physiological Characteristics of Surface Receptors of Gram Negative Bacteria
Mini-Reviews in Medicinal Chemistry Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Inpatient Diabetes Management in Non-ICU Settings: Evidence and Strategies
Current Diabetes Reviews Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Probing Gallic Acid for Its Broad Spectrum Applications
Mini-Reviews in Medicinal Chemistry Enhanced Hyperthermia Induced by MDMA in Parkin Knockout Mice
Current Neuropharmacology Restoration of Cardiomyocyte Function in Streptozotocin-Induced Diabetic Rats after Treatment with Vanadate in a Tea Decoction
Current Pharmaceutical Biotechnology Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk
Current Drug Abuse Reviews Neurotransmitters, Psychotropic Drugs and Microglia: Clinical Implications for Psychiatry
Current Medicinal Chemistry Target Recognition in SAR Image by Joint Classification of Target Region and Shadow
Recent Advances in Electrical & Electronic Engineering Neurotoxicity of β-Amyloid Protein: Oligomerization, Channel Formation and Calcium Dyshomeostasis
Current Pharmaceutical Design The Structural Alteration and Aggregation of Bovine Lens Gamma-Crystallin by Homocysteinylation; The Pathomechanism Underlying Cataract Development During Hyperhomocysteinimia
Protein & Peptide Letters Biomarkers Linking PCB Exposure and Obesity
Current Pharmaceutical Biotechnology Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Prolactin Protects Against the Methamphetamine-Induced Cerebral Vascular Toxicity
Current Neurovascular Research An Overview of Phytochemical and Pharmacological Profile of <i>Morus alba</i> Linn
Current Bioactive Compounds A Review on the Antinociceptive Effects of Mitragyna speciosa and Its Derivatives on Animal Model
Current Drug Targets Performance of Genotype MTBDRplus in the Detection of Resistance to Rifampicin and Isoniazid Among Clinical Mycobacteria Isolates in Ilorin, Nigeria
Current HIV Research Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Current Pharmaceutical Design